This year AstraZeneca PLC Biopharmaceuticals President Ruud Dobber is focused on executing on the company's expansion into kidney disease with the launch of Lokelma (sodium zirconium cyclosilicate) underway for hyperkalemia and a second potential approval, roxadustat, anticipated later in 2020.
Dobber, who oversees AstraZeneca's global drug portfolio outside of oncology, talked with Scrip at the J.P. Morgan Healthcare conference in...